Medication info

Innoen Empagliflozin 25 mg

Prescription medicationTabletOral
Ingredient · strength
Empagliflozin›25mg / 1 tablet
Manufacturer / importer
HK Inno.N Co., Ltd.
Appearance
Pale yellow oval film-coated tablet
Packaging
30 tablets - 30 tablets/PTP[(10 tablets/PTP×3)], 10 tablets - 10 tablets/PTP[(10 tablets/PTP×1)]
Approval status
Active

MFDS item code 202105730 · Approved 2021.08.04

Summary

Main use
Improvement of glycemic control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The recommended dose of this medicine is 10 mg once daily, both as monotherapy and as add-on combination therapy with other blood glucose-lowering agents, such as insulin. If 10 mg of this medicine is well tolerated and additional glycemic control is needed, the dose may be increased to 25 mg once daily. When this medicine is administered in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see Precautions for Use, section 3. Adverse Reactions). This medicine may be taken with or without food. Swallow the tablet whole. If you miss a dose, take it as soon as you remember. Do not take a double dose in one day. Special populations •Patients with renal impairment No dose adjustment is necessary in patients with mild renal impairment. Treatment with this medicine should not be initiated in patients with an estimated glomerular filtration rate (eGFR) below 60 ml/min/1.73m2 [or CrCl < 60 ml/min]. In patients who tolerate this medicine well but have a persistent estimated glomerular filtration rate below 60ml/min/1.73m2 [or CrCl < 60 ml/min], the dose should be adjusted to or maintained at 10 mg once daily. This medicine should be discontinued if the estimated glomerular filtration rate decreases to below 45 ml/min/1.73m2 [or CrCl < 45 ml/min]. Do not use this medicine in patients with end-stage renal disease (ESRD) or those on dialysis, as efficacy is not expected. •Patients with hepatic impairment No dose adjustment is necessary in patients with mild or moderate hepatic impairment. Use of this medicine is not recommended in patients with severe hepatic impairment, as it has not been studied in this population. •Elderly patients No dose adjustment based on age is necessary. Renal function and the risk of volume depletion should be considered in patients aged 75 years and older. Initiation of treatment with this medicine is not recommended in patients aged 85 years and older because clinical experience is limited (see Precautions for Use, section 4. General Precautions).

Ingredients

Manufacturer
HK Inno.N Co., Ltd.

Efficacy & effects

Improvement of glycemic control in adults with type 2 diabetes mellitus

  • Type 2 diabetes
  • impaired blood sugar control
  • cardiovascular disease
View approved original text

This medication is used as an adjunct to diet and exercise to improve blood sugar control in adults with type 2 diabetes. It can be used alone or in combination with other medications. In particular, in patients with type 2 diabetes whose blood sugar is not adequately controlled and who have cardiovascular disease, caution is needed for the occurrence of cardiovascular events, and guidance from a specialist should be sought. This medication helps with diabetes management by improving blood sugar control.

How to take

Adult dose

The recommended dose of this medicine is 10 mg once daily, both as monotherapy and as add-on combination therapy with other blood glucose-lowering agents, such as insulin. If 10 mg of this medicine is well tolerated and additional glycemic control is needed, the dose may be increased to 25 mg once daily. When this medicine is administered in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see Precautions for Use, section 3. Adverse Reactions). This medicine may be taken with or without food. Swallow the tablet whole. If you miss a dose, take it as soon as you remember. Do not take a double dose in one day. Special populations •Patients with renal impairment No dose adjustment is necessary in patients with mild renal impairment. Treatment with this medicine should not be initiated in patients with an estimated glomerular filtration rate (eGFR) below 60 ml/min/1.73m2 [or CrCl < 60 ml/min]. In patients who tolerate this medicine well but have a persistent estimated glomerular filtration rate below 60ml/min/1.73m2 [or CrCl < 60 ml/min], the dose should be adjusted to or maintained at 10 mg once daily. This medicine should be discontinued if the estimated glomerular filtration rate decreases to below 45 ml/min/1.73m2 [or CrCl < 45 ml/min]. Do not use this medicine in patients with end-stage renal disease (ESRD) or those on dialysis, as efficacy is not expected. •Patients with hepatic impairment No dose adjustment is necessary in patients with mild or moderate hepatic impairment. Use of this medicine is not recommended in patients with severe hepatic impairment, as it has not been studied in this population. •Elderly patients No dose adjustment based on age is necessary. Renal function and the risk of volume depletion should be considered in patients aged 75 years and older. Initiation of treatment with this medicine is not recommended in patients aged 85 years and older because clinical experience is limited (see Precautions for Use, section 4. General Precautions).

Precautions

This medication should not be used in certain patients. Patients with allergies to the main ingredient or components, individuals with type 1 diabetes or diabetic ketoacidosis should not be administered this drug. Patients with severely impaired kidney function or end-stage renal disease, and patients undergoing dialysis should also not take this medication. Additionally, it should not be administered to patients with genetic metabolic disorders such as lactase intolerance. In patients with mild kidney impairment, it should be administered with caution, and regular kidney function tests are important. If kidney function continuously worsens, this medication should be discontinued. It is not recommended for severely ill patients with heart failure. When taken with blood glucose-lowering medications such as insulin or sulfonylureas, there is a risk of hypoglycemia, and dosage adjustments may be necessary. Adverse reactions that may occur while taking this medication include hypoglycemia, genital infections, urinary tract infections, increased urination, and decreased blood volume, with special caution being necessary for the elderly due to a higher risk of fluid loss. Severe metabolic disturbances such as ketoacidosis may occur, so if symptoms appear, immediate treatment should be sought, and this medication is not to be used in the treatment of type 1 diabetes. Reports of liver damage have also been made, so patients with liver dysfunction should exercise caution, and special attention is needed for the elderly or those at risk of fluid loss. There is a significant risk of severe urinary tract infections such as urosepsis and pyelonephritis, so immediate treatment should be sought if symptoms of infection arise. There is also an increased risk of genital fungal infections, so patients with a history of infections should be closely monitored. This medication may show positive results in urine glucose tests, so be mindful when interpreting test results. Caution is needed when driving or operating machinery due to the risk of hypoglycemia, especially when taken in combination with insulin or sulfonylureas. While no specific toxicities have been reported from overdose, appropriate treatment is needed depending on the clinical condition. Use during pregnancy is not recommended, and if pregnancy is confirmed, the medication should be discontinued. It is safest to stop breastfeeding while taking this medication. Safety and efficacy in pediatric patients have not been established, so it should not be administered to patients under 18 years of age. Regular kidney function tests and monitoring for symptoms of infection are needed during the course of this medication, and any abnormal symptoms should prompt immediate consultation with healthcare professionals.

Side effects

  • Hypoglycemia
  • ketoacidosis
  • vulvovaginitis
  • balanitis
  • other genital infections
  • increased urination
  • difficulty urinating
  • interstitial nephritis
  • itching
  • rash
Show 12 more
  • urticaria
  • angioedema
  • decreased fluid volume
  • thirst
  • increased serum lipids
  • increased serum creatinine
  • decreased glomerular filtration rate
  • increased hematocrit
  • urinary tract infection
  • urosepsis
  • pyelonephritis
  • perineal necrosis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to prevent exposure to air and moisture, and it is best stored at room temperature between 1°C and 30°C. Storing it this way helps to maintain the medication's effectiveness.

Appearance and packaging

Appearance

Pale yellow oval film-coated tablet

Package unit

30 tablets - 30 tablets/PTP[(10 tablets/PTP×3)], 10 tablets - 10 tablets/PTP[(10 tablets/PTP×1)]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.